{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT04218409",
            "orgStudyIdInfo": {
                "id": "IRB201902618-N"
            },
            "secondaryIdInfos": [
                {
                    "id": "OCR30384",
                    "type": "OTHER",
                    "domain": "UF OnCore"
                },
                {
                    "id": "1K01DA052673-01A1",
                    "type": "NIH",
                    "link": "https://reporter.nih.gov/quickSearch/1K01DA052673-01A1"
                }
            ],
            "organization": {
                "fullName": "University of Florida",
                "class": "OTHER"
            },
            "briefTitle": "Opioid-Sparing and Pain-Reducing Properties of Syntocinon: A Dose-Effect Determination",
            "officialTitle": "Opioid-Sparing and Pain-Reducing Properties of Syntocinon: A Dose-Effect Determination",
            "therapeuticArea": [
                "Other"
            ],
            "study": "opioid-sparing-and-pain-reducing-properties-of-syntocinon-a-dose-effect-determination"
        },
        "statusModule": {
            "statusVerifiedDate": "2023-12",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2021-09-02",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2026-12-31",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2026-12-31",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2020-01-02",
            "studyFirstSubmitQcDate": "2020-01-03",
            "studyFirstPostDateStruct": {
                "date": "2020-01-06",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2023-12-07",
            "lastUpdatePostDateStruct": {
                "date": "2023-12-08",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "University of Florida",
                "class": "OTHER"
            },
            "collaborators": [
                {
                    "name": "National Institute on Drug Abuse (NIDA)",
                    "class": "NIH"
                }
            ]
        },
        "oversightModule": {
            "oversightHasDmc": true,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false,
            "isUsExport": false
        },
        "descriptionModule": {
            "briefSummary": "Some research suggests that administration of oxytocin with oxycodone may reduce its abuse liability and improve its ability to reduce pain. In a 6-session laboratory study, the investigators will be evaluating the effects of oxycodone and oxytocin (combined and separately, across sessions) on experimentally-induced pain, subjective effects, decision-making, and activation of different neural substrates.",
            "detailedDescription": "The overall project goals are to determine oxytocin effects on oxycodone's subject-rated abuse liability, experimental pain, and to describe the neurobehavioral mechanisms underlying interindividual differences in these effects. Generally healthy individuals (determined via medical history review and a screening session) will, after informed consent, self-administer intranasal oxytocin (or placebo, containing the same ingredients but no oxytocin) shortly after oral oxycodone or placebo in a non-residential, double-blind, randomized, placebo-controlled, within-subjects laboratory study. Prescreening will assure MRI eligibility and drug application safety and, using a validated, comprehensive pain history interview, determine previous or existing chronic pain conditions, including current pain medication use."
        },
        "conditionsModule": {
            "conditions": [
                "Pain"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "EARLY_PHASE1"
            ],
            "designInfo": {
                "allocation": "RANDOMIZED",
                "interventionModel": "CROSSOVER",
                "interventionModelDescription": "This is a within-participant study so that each participant receives all conditions.",
                "primaryPurpose": "BASIC_SCIENCE",
                "maskingInfo": {
                    "masking": "DOUBLE",
                    "whoMasked": [
                        "PARTICIPANT",
                        "OUTCOMES_ASSESSOR"
                    ]
                }
            },
            "enrollmentInfo": {
                "count": 45,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "oxycodone (5mg) + intranasal oxytocin (48 IU)",
                    "type": "ACTIVE_COMPARATOR",
                    "description": "Combined effects of oxycodone and oxytocin",
                    "interventionNames": [
                        "Drug: OxyCODONE 5 mg Oral Tablet",
                        "Drug: Oxytocin nasal spray"
                    ]
                },
                {
                    "label": "Oral oxycodone (5mg) + intranasal placebo",
                    "type": "ACTIVE_COMPARATOR",
                    "description": "Separate effects of oxycodone. As is standard methodology in abuse liability and pain assessments a placebo condition will be included for each drug in order to compare the abuse liability and pain assessments change from placebo",
                    "interventionNames": [
                        "Drug: OxyCODONE 5 mg Oral Tablet",
                        "Other: Placebo oxytocin"
                    ]
                },
                {
                    "label": "oxytocin+placebo",
                    "type": "ACTIVE_COMPARATOR",
                    "description": "Separate effects of oxytocin. As is standard methodology in abuse liability and pain assessments a placebo condition will be included for each drug in order to compare the abuse liability and pain assessments change from placebo",
                    "interventionNames": [
                        "Drug: Oxytocin nasal spray",
                        "Other: Placebo Oxycodone"
                    ]
                },
                {
                    "label": "placebo+placebo",
                    "type": "SHAM_COMPARATOR",
                    "description": "Serves as the control",
                    "interventionNames": [
                        "Other: Placebo Oxycodone",
                        "Other: Placebo oxytocin"
                    ]
                },
                {
                    "label": "Oral oxycodone (2.5mg) + intranasal oxytocin (48 IU)",
                    "type": "ACTIVE_COMPARATOR",
                    "description": "Combined effects of oxycodone and oxytocin",
                    "interventionNames": [
                        "Drug: Oxytocin nasal spray",
                        "Drug: OxyCODONE 2.5 mg Oral Tablet"
                    ]
                },
                {
                    "label": "Oral oxycodone (2.5mg) + intranasal placebo",
                    "type": "ACTIVE_COMPARATOR",
                    "description": "Separate effects of oxycodone. As is standard methodology in abuse liability and pain assessments a placebo condition will be included for each drug in order to compare the abuse liability and pain assessments change from placebo",
                    "interventionNames": [
                        "Other: Placebo oxytocin",
                        "Drug: OxyCODONE 2.5 mg Oral Tablet"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "OxyCODONE 5 mg Oral Tablet",
                    "description": "Oral oxycodone 5 mg orally",
                    "armGroupLabels": [
                        "Oral oxycodone (5mg) + intranasal placebo",
                        "oxycodone (5mg) + intranasal oxytocin (48 IU)"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Oxytocin nasal spray",
                    "description": "Intranasal oxytocin administration (48 IU)",
                    "armGroupLabels": [
                        "Oral oxycodone (2.5mg) + intranasal oxytocin (48 IU)",
                        "oxycodone (5mg) + intranasal oxytocin (48 IU)",
                        "oxytocin+placebo"
                    ]
                },
                {
                    "type": "OTHER",
                    "name": "Placebo Oxycodone",
                    "description": "Oxycodone 0 mg orally",
                    "armGroupLabels": [
                        "oxytocin+placebo",
                        "placebo+placebo"
                    ]
                },
                {
                    "type": "OTHER",
                    "name": "Placebo oxytocin",
                    "description": "Intranasal placebo administration",
                    "armGroupLabels": [
                        "Oral oxycodone (2.5mg) + intranasal placebo",
                        "Oral oxycodone (5mg) + intranasal placebo",
                        "placebo+placebo"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "OxyCODONE 2.5 mg Oral Tablet",
                    "description": "Oral oxycodone 2.5 mg orally",
                    "armGroupLabels": [
                        "Oral oxycodone (2.5mg) + intranasal oxytocin (48 IU)",
                        "Oral oxycodone (2.5mg) + intranasal placebo"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Subject-rated abuse liability",
                    "description": "Using a Visual Analog Scale with scoring as 0=not at all, 20=possibly mild, 40=definitely mild, 60=moderately, 80=strongly, and 100=extremely, or any number in between. Testing occurs only in the context of 4 sessions due to a minimum of a one week washout period in between each session.",
                    "timeFrame": "up to 6 weeks."
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Individuals fluent in English will participate.\n* Must report recreational use of opioids.\n* Be within 20% of their ideal body weight.\n* Are not currently experiencing chronic pain (pain on most days during the past 3 months)\n* Have a systolic blood pressure of \\<=140 and diastolic blood pressure of \\<= 90, and a heart rate \\<= 90 beats per minute.\n* Participants must also have a normal electrocardiogram (EKG) reading and bloodwork indicating no major health contraindications.\n\nExclusion criteria:\n\n* Significant current physical disease or major psychiatric disorder.\n* No self-reported current interest in drug abuse treatment.\n* Women who are pregnant or nursing.\n* Any comorbid illicit substance use disorders or current clinically significant withdrawal for any abused drug excluding nicotine and caffeine.\n* Any conditions that preclude safety in the MRI scanner, such as: implanted electrical devices (e.g., cardiac pacemaker, neurostimulator); implanted metallic clips or pins (e.g., aneurysm clip); a history of working with metal (unless able to demonstrate participant is MRI safe), and claustrophobia.",
            "healthyVolunteers": true,
            "sex": "ALL",
            "minimumAge": "21 Years",
            "maximumAge": "45 Years",
            "stdAges": [
                "ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Lauren Nieder",
                    "role": "CONTACT",
                    "phone": "352-294-1067",
                    "email": "lauren.nieder@ufl.edu"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Meredith Berry, PhD",
                    "affiliation": "University of Florida",
                    "role": "PRINCIPAL_INVESTIGATOR"
                }
            ],
            "locations": [
                {
                    "facility": "University of Florida",
                    "status": "RECRUITING",
                    "city": "Gainesville",
                    "state": "Florida",
                    "zip": "32611",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 29.65163,
                        "lon": -82.32483
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "NO"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "browseLeaves": [
                {
                    "id": "M13066",
                    "name": "Pain",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC23",
                    "name": "Symptoms and General Pathology"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                }
            ]
        },
        "interventionBrowseModule": {
            "meshes": [
                {
                    "id": "D000010098",
                    "term": "Oxycodone"
                },
                {
                    "id": "D000010121",
                    "term": "Oxytocin"
                }
            ],
            "ancestors": [
                {
                    "id": "D000010120",
                    "term": "Oxytocics"
                },
                {
                    "id": "D000012102",
                    "term": "Reproductive Control Agents"
                },
                {
                    "id": "D000045505",
                    "term": "Physiological Effects of Drugs"
                },
                {
                    "id": "D000000701",
                    "term": "Analgesics, Opioid"
                },
                {
                    "id": "D000009294",
                    "term": "Narcotics"
                },
                {
                    "id": "D000002492",
                    "term": "Central Nervous System Depressants"
                },
                {
                    "id": "D000000700",
                    "term": "Analgesics"
                },
                {
                    "id": "D000018689",
                    "term": "Sensory System Agents"
                },
                {
                    "id": "D000018373",
                    "term": "Peripheral Nervous System Agents"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M4033",
                    "name": "Analgesics, Opioid",
                    "relevance": "LOW"
                },
                {
                    "id": "M13020",
                    "name": "Oxycodone",
                    "asFound": "Where",
                    "relevance": "HIGH"
                },
                {
                    "id": "M13041",
                    "name": "Oxytocin",
                    "asFound": "State",
                    "relevance": "HIGH"
                },
                {
                    "id": "M4032",
                    "name": "Analgesics",
                    "relevance": "LOW"
                },
                {
                    "id": "M12245",
                    "name": "Narcotics",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "Analg",
                    "name": "Analgesics"
                },
                {
                    "abbrev": "CNSDep",
                    "name": "Central Nervous System Depressants"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                },
                {
                    "abbrev": "Repr",
                    "name": "Reproductive Control Agents"
                }
            ]
        }
    },
    "hasResults": false
}